Two patients. Same disease. Same drug. Completely different results. What if the secret to choosing the right treatment is already written in your skin?

Two people can have the same diagnosis, appear to have similar disease and receive the same medication, yet experience completely different results. For patients with moderate-to-severe plaque psoriasis, that can mean cycling through biologic therapies while physicians search for the treatment that works best for the individual. Mindera Health says real-world response rates to available biologics range from 46–56%, highlighting the challenge of treatment selection. 

In this segment of Health Uncensored, we head to San Diego to meet practicing dermatologist Dr. Neal Bhatia and explore what precision medicine could mean for psoriasis patients. Back in studio, Dr. Drew sits down with Mindera Health Chief Scientific Officer and co-founder Tobin Dickerson, Ph.D., and Subtilitas co-founder Michael Howell, Ph.D., to follow a sample from California into a much bigger world of molecular medicine. Mindera’s Mind.Px test combines transcriptomic analysis with data science to provide information intended to help physicians determine which class of biologic therapy a patient with moderate-to-severe plaque psoriasis may be most likely to respond to. It’s a glimpse into a future of medicine that asks a very different question, not simply “What usually works for this disease?” but “What might work for this particular patient?”